Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 3/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9189874 | 0.87 | SLC1A3 (0.30) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8512652 | 0.87 | — | — | |
| SCHEMBL2728771 | 0.79 | CTSL (0.32) | SLC1A3SLC1A2SLC1A1CYP1A2CTSL | |
| SCHEMBL6458793 | 0.79 | CTSL (0.32) | SLC1A3SLC1A2SLC1A1CYP1A2CTSL | |
| SCHEMBL7738017 | 0.78 | CYP1A2 (0.35) | CYP1A2CTSLCTSBCTSKLMNA | |
| SCHEMBL7739318 | 0.78 | CYP1A2 (0.35) | CYP1A2CTSLCTSBCTSKLMNA | |
| SCHEMBL7739287 | 0.78 | CYP1A2 (0.35) | CYP1A2CTSLCTSBCTSKLMNA | |
| SCHEMBL7739395 | 0.78 | CYP1A2 (0.35) | CYP1A2CTSLCTSBCTSKLMNA | |
| SCHEMBL7738582 | 0.78 | CYP1A2 (0.35) | CYP1A2CTSLCTSBCTSKLMNA | |
| SCHEMBL24719157 | 0.76 | TDP1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189724-B2 | Quinoxaline derivatives having antiviral activity | VALEANT RESEARCH AND DEVELOPMENT (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050026923-A1 | Quinoxaline derivatives having antiviral activity | BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA) (PL) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026923-A1 | Quinoxaline derivatives having antiviral activity | IRF3, MAVS, EIF2AK2 | SLC1A3 2916/4885SLC1A2 3756/4885SLC1A1 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.